IL6 and cancer: IL-6 and Activin A have a synergic role in inducing Noggin overexpression that causes NMJ impairment and atrophy, whereas treatment aimed to increase BMP signaling attenuate muscle atrophy during cancer cachexia [182] (Figure 3).